PSA test alone not an ideal predictor of prostate cancer

	Tweet

Recent studies suggest that testing blood for prostate specific antigen (PSA) alone does not produce an ideal predictor of prostate cancer, and emerging data suggest this is especially true for obese men.

A recent study by Oregon Health & Science University Cancer Institute researchers shows that a simple adjustment in how clinical measurements are interpreted in the diagnosis of prostate cancer can accurately predict the presence of prostate cancer in obese men.

“Some studies have shown that obese men are more likely to have deadly prostate cancer, yet diagnostic tools like PSA are less likely to accurately predict the presence of cancer in this population,” said Mark Garzotto, M.D., an Oregon Health & Science University Cancer Institute researcher presented the study at the 2006 annual meeting of the American Society of Clinical Oncology.

PSA is a protein made only by prostate cells. Certain prostate conditions, including prostate cancer, are associated with high levels of PSA in the blood. However, obesity or high body mass index (BMI) has been tied to lower PSA levels. BMI measures weight in relation to height.

Compounding this diagnostic difficulty is that increasing BMI leads to increasing prostate size, but, again, lower PSA. Larger prostates produce more PSA in men with normal BMI’s, not less.

“This is a perfect storm in the diagnostic world,” said Garzotto, who has studied and developed more accurate methods of diagnosing prostate cancer. Today, just one in four men who receive prostate biopsies after positive screening tests for cancer actually are diagnosed with the disease. “We needed a better understanding of how BMI affects prostate cancer diagnosis and what can be done about it,” he said.

For this study, Garzotto and his colleagues conducted a retrospective study of clinical data for 647 men with a PSA of 10 or greater and who had an ultrasound-guided prostate biopsy. They analyzed age, BMI, digital rectal exam, PSA, prostate volume, PSA density (PSA divided by prostate volume), hypoechoic lesions found in ultrasound examinations, and cancer on biopsy.

Researchers found that in cases with men whose BMI was 25 or above, a lower PSA density (PSAD) calculation needed to be used to accurately predict who had cancer. “This is important because the tendency for obese men to have lower PSA values and higher prostate volumes lead to a lower overall PSAD,” Garzotto said.

“We discovered that one set of rules apply to men with low to normal body mass index and another set of rules apply to men with high body mass index,” Garzotto said. “This new risk factor beats all the prior predictors in a race and, importantly, it helps us provide appropriate care for the 66 percent of men in the United States who are overweight or obese.”

http://www.ohsu.edu

RELATED STORIES:
Scientists discover way to block growth of prostate cancer cells   Baldness drug could mask prostate cancer marker   Dramatic Outcomes in Prostate Cancer Study   Drug Shows Activity in Men with Advanced Prostate Cancer   Young men with prostate cancer benefit from radiation therapy   Advanced-Stage Prostate Cancer Patients Experience 20-Year Survival Rates With Surgery   Excessive Multivitamin Use May Raise Risk for Prostate Cancer   New Targeted Therapy Effective in Treating Advanced Prostate Cancer   Red, processed meats linked to prostate cancer   Gene test may help spot lethal prostate tumors   Researchers Locate and Image Prostate Cancer as It Spreads to the Lymph Nodes   Men often not told of prostate cancer risks: study   Prediction models help determine likelihood of erectile function after treatment for prostate cancer   What is the role of focal therapy in low-risk prostate cancer?   Prostate cancer therapy not tied to bladder cancer   Prostate Cancer Clinical Findings   Don’t Give Up on Prostate Cancer Screening Just Yet   New Finding Suggests Prostate Biopsy is Not Always Necessary   Low-Income Men More Likely to be Diagnosed with Advanced Prostate Cancers   Low PSA may not rule out prostate cancer   Finnish researchers find a compound that prevents the growth of prostate cancer cells   Chlordecone exposure and risk of prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]